VCM si ssaeatidco hwit netigicnf arnog nlapnrsatt net.ptisa VCM si ttrensamdit iva alseux tnccaot, angro rltpt,anans or lalcveyrti avi .clatepna teavincRoait of CVM uorcsc in eht miersppdunmeo.uss
agrnO anstprltna atneptis aer at an aerdncesi ksir of VMC euanmoni.p
eh asw eenvr engiv cvngriaciol - i usde tath sa a lceu reov tpaarntnls ocetrenji
Wyh uowdl isth ton be uaetc artntpnsla eitecrojn ileadgn to A?RSD Teh necraeitni is vedlet,ea dna I ese yan oerans ywh it luwdo be ledaevte ebynod jcteinoer
via @sammyj98 via UpToDate:
Universal prophylaxis with valganciclovir or ganciclovir is typically given to patients at risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy often depends on the type of organ transplanted, the risk status of the patient, and individual institutional practice. Some transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations.
submitted by โamorah(115)
It can be re-accessed by making a purchase.
Purchase your membership here
$279$49eervF ;g&-t erul out tlfe rtunlvaiecr rafiuel SM-M PXT ishrpaopxly ;t-&g leur tou mntPyciseuos y riKcinvodieje rttanaspln btu on RCB/WBC in nuire ;g&-t rleu uto rtaslaptnn ntijeerco
iagnvLe VMC dna aciatylp cromicuybtmae sa the einrginam tow .spioton VMC si mroe keylli in a sanlprtnat pit.ntae
$279$49